Congressional hearing in Brazil will discuss the efficacy of generic medicines

26 May 2014

The Brazilian Commission for Consumer Protection will soon hold a hearing to discuss the effectiveness of generic drugs, writes Juliane Carvalho writing on Brazil Pharma News (http://www.brazilpharmanews.com).

According to the Committee's chairman, Sergio Brito (PSD - BA), there are frequent complaints from health professionals and consumers that the effectiveness of generics is limited.

"Some health care professionals, including doctors of the Unified Health System (SUS) and hospitals who treat serious diseases such as cancer have reported that they had to replace generic drugs in the middle of treatment because these drugs do not present the expected effects for the active ingredients," says Mr Brito.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >